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Abstract: Reliable, comparable information about the
main causes of disease and injury in populations, and how
these are changing, is a critical input for debates about
priorities in the health sector. Traditional sources of
information about the descriptive epidemiology of
diseases, injuries, and risk factors are generally incom-
plete, fragmented, and of uncertain reliability and
comparability. The Global Burden of Disease (GBD) study
has provided a conceptual and methodological frame-
work to quantify and compare the health of populations
using a summary measure of both mortality and disability,
the disability-adjusted life year (DALY). This paper
describes key features of the Global Burden of Disease
analytic approach, which provides a standardized mea-
surement framework to permit comparisons across
diseases and injuries, as well as risk factors, and
a systematic approach to the evaluation of data. The
paper describes the evolution of the GBD, starting from
the first study for the year 1990, summarizes the
methodological improvements incorporated into GBD
revisions for the years 2000–2004 carried out by the
World Health Organization, and examines priorities and
issues for the next major GBD study, funded by the Bill &
Melinda Gates Foundation, and commencing in
2007. The paper presents an overview of summary
results from the Global Burden of Disease study 2002, with
a particular focus on the neglected tropical diseases, and
also an overview of the comparative risk assessment for
26 global risk factors. Taken together, trypanosomiasis,
Chagas disease, schistosomiasis, leishmaniasis, lymphatic
filariasis, onchocerciasis, intestinal nematode infections,
Japanese encephalitis, dengue, and leprosy accounted for
an estimated 177,000 deaths worldwide in 2002, mostly in
sub-Saharan Africa, and about 20 million DALYs, or 1.3%
of the global burden of disease and injuries. Further
research is currently underway to revise and update these
estimates.
Introduction
Governments and international agencies are faced with setting
priorities for health research and investment in health systems and
health interventions in a context of increasing health care costs,
increasing availability of effective interventions, and numerous and
diverse priorities and interest groups. Evidence on the magnitude
and trends of diseases and their causes should be a critical input to
decision making at the global, national, and local levels. Broad
evaluation of the effectiveness of health systems and major health
programs and policies also requires assessments of the causes of
loss of health that are comparable not only across populations, but
also over time.
The World Bank’s 1993 World Development Report on Investing
in Health recommended cost-effective intervention packages for
countries at different levels of development [1]. Underpinning
these analyses was the first Global Burden of Disease (GBD) study,
carried out by Chris Murray at Harvard University and Alan
Lopez at the World Health Organization (WHO), in collaboration
with a global network of over 100 scientists [1–4]. To produce
comprehensive, valid, reliable, and comparable information of
maximum relevance to decision making, the GBD analytic
framework included several novel attributes:
N Information on causes both of premature mortality and of
morbidity, impairment, and disability was combined to present
a balanced, comprehensive assessment of health problems.
This helps appropriately represent the impact of conditions
such as onchocerciasis, trachoma, filariasis, intestinal hel-
minthes, schizophrenia, depression, and paralysis, which cause
great suffering and loss of health but little mortality.
N The study used a standard unit of health measurement, namely
disability-adjusted life years (DALYs). The results can then
easily be incorporated into comparisons of costs and effects of
different interventions to reduce the burden of disease. Use of
a common metric also facilitates the quantification of disease
burden from both diagnostic categories of the International
Classification of Disease and Injuries (ICD), and the major risk
factors that cause those health outcomes.
N All disease and injury causes were included in the analysis (this
avoids the problem of over-inclusiveness of single cause studies,
and of incompatible mortality claims for different causes). This
in turn required the development of methods to estimate
missing data.
This paper describes the GBD framework for integrating,
validating, analyzing, and disseminating fragmentary information
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policy and planning.
Global Burden of Disease 1990 Study
The original GBD study was commissioned in 1992 by the
World Bank to provide a comprehensive assessment of disease
burden in 1990 from more than 100 diseases and injuries, and
from 10 selected risk factors for the world and eight major World
Bank regions [1–3,5–7]. Earlier attempts to quantify global cause
of death patterns [8,9] had been largely restricted to broad cause
of death groups.
As well as generating consistent estimates of mortality, in-
cidence, prevalence, and disability for over 130 causes by age, sex,
and world region, the GBD study introduced a new metric—the
DALY—which summarized the loss of health due to mortality and
morbidity combined. The DALY is examined in more detail in the
following section. Much of the comment and criticism of the GBD
study has focused on the construction of DALYs [10–13],
particularly the social choices around age-weights and severity
scores for disabilities, and relatively little around the large
uncertainty in the basic descriptive epidemiology, especially in
Africa, which is likely to be far more consequential for setting
health priorities [14]. These criticisms are examined in more detail
in the Discussion section below.
The GBD study developed methods for assessing causes of
burden for which there were limited data and considerable
uncertainty, to ensure that such causes were not implicitly
considered to have zero burden. To prepare estimates of the
incidence, prevalence, duration, and mortality from over 500
sequelae of more than 100 diseases or injuries, a mathematical
model, DISMOD, was developed for the 1990 GBD study to
convert partial, often nonspecific data on disease/injury occur-
rence into a consistent age description of the basic epidemiological
parameters in each region [15].
The leading causes of disease burden in 1990 were childhood
diseases (lower respiratory diseases, diarrhoeal diseases, and
perinatal causes such as birth asphyxia, birth traumas, and low
birth weight), in part because of the greater weight given to deaths
at younger ages by the DALY. Depression ranked fourth globally,
ahead of ischemic heart disease, cerebrovascular disease, tubercu-
losis, and measles. Road traffic injuries also ranked in the top 10
causes of DALYs worldwide. The results of the original GBD
study were surprising to many health policy makers, who were
more familiar with the pattern of causes represented in mortality
statistics. Neuropsychiatric disorders and injuries were major
causes of lost years of healthy life as measured by DALYs, and
were greatly undervalued when measured by mortality alone
[4,16]. More broadly, noncommunicable diseases, including
neuropsychiatric disorders, were estimated to have caused 41%
of the global burden of disease in 1990, only slightly less than
communicable, maternal, perinatal, and nutritional conditions
combined (44%), with 15% due to injuries.
The methods and findings of the original (1990) GBD study
have been widely published [1–5,16], and the GBD approach has
been widely adopted by countries and health development
agencies alike as the standard for health accounting. The methods
and findings of the original GBD study stimulated quite a number
of national disease burden studies of varying scope and
methodological rigour during the 1990s. The earliest comprehen-
sive studies were undertaken for Mexico and Mauritius [17,18],
followed by studies in the late 1990s in the Netherlands and
Australia [19–22]. In the last few years, comprehensive national
burden of disease studies have also been carried out in countries
such as Brazil, Malaysia, Turkey, South Africa, Zimbabwe,
Thailand, and the United States, and studies are underway in
Canada and several other countries.
The DALY—Construction and Concepts
To assess disease burden, a time-based metric that measured
both premature mortality (years of life lost, or YLLs) and disability
(years of life lived with a disability, weighted by the severity of the
disability, or YLDs) was developed for the GBD 1990 study [23].
The sum of the two components, namely DALYs, provides
a measure of the future stream of healthy life lost as a result of the
incidence of specific diseases and injuries in 1990. One lost DALY
can be thought of as one lost year of ‘‘healthy’’ life (either through
death or illness/disability), and total DALYs (the burden of
disease) as a measurement of the gap between the current health of
a population and an ideal situation where everyone in the
population lives into old age in full health. A more complete
account of the DALY, and the value choices it incorporates, is
given elsewhere [23–25]. DALYs are a particular formulation of
the more general quality-adjusted life years (QALYs) measure
proposed by Zeckhauser and Shepard in 1976 and widely used in
cost-effectiveness analyses for health interventions [26]. DALYs
measure health loss in populations against a normative standard,
whereas QALYs are usually used to quantify health gains for
interventions. For cost-effectiveness analyses, the mechanics of
estimating DALYs averted and QALYs gained are virtually
identical [27]. The approaches potentially differ only in the
quantification and interpretation of the weighting system (dis-
cussed further in the Discussion below).
The YLLs for deaths at a given age x are calculated from the
number of deaths, dx, at that age multiplied by a global standard
life expectancy, Lx, which is a function of age x. The GBD 1990
study chose not to use an arbitrary age cut-off such as 65 or
70 years in the calculation of YLLs, but rather specified the loss
function Lx in terms of the life expectancies at various ages in
standard life tables, with life expectancy at birth fixed at 82.5 years
for females and 80.0 years for males (Figure 1). The loss function
was specified to be the same for all deaths of a given age and sex,
in all regions of the world. This standard has continued to be used,
and should not be confused with the country-specific life tables
estimated for all WHO Member States for 2002, which summarize
all-cause mortality rates in 2002 by age and sex.
YLDs for a particular cause in a particular time period are
calculated by multiplying the number of incident cases ix, at each
age x in that period, by the average duration of the disease for each
age of incidence, lx, and a weight factor dwx, that reflects the
severity of the disease on a scale from 0 (full health) to 1 (dead).
YLDs are generally calculated either for the average incident case
of the disease, or for one or more disabling sequelae of the disease.
For example, YLDs for onchocerciasis are calculated by adding
the YLDs for the sequelae of low vision, blindness, and itchy
dermatitis. The ‘‘valuation’’ of time lived in nonfatal health states
formalizes and quantifies social preferences for different states of
health as disability weights (dwx). Disability weights are further
discussed later in this paper.
Murray and Lopez chose to apply a 3% time discount rate to
the years of life lost in the future to estimate the net present value
of years of life lost in calculating DALYs, and also incorporated
nonuniform age weights that gave less weight to years of healthy
life lost in early childhood or at older ages [23]. Time discounting
is applied to the years of life lost in the future for consistency with
the measurement of health outcomes in cost-effectiveness analyses;
to prevent giving excessive weight to deaths at younger ages; and
Review
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that investment in research or disease eradication has a nonzero
chance of succeeding, then without discounting, all current health
expenditure should be shifted to such investment because the
future stream of benefits is infinite [28].
The introduction ofnonuniformage weightswas based on human
capital arguments and on a number of studies that suggest the
existenceofabroadsocialpreferencetovalueayearlivedbyayoung
adult more highly than a year lived by a young child or an older
person. The particular age weights used in the GBD study result in
greater weight being given to all deaths below age 39 compared with
deaths at older ages. When discounting and age weighting are both
applied, a death in infancy corresponds to 33 DALYs, while deaths
at ages five to 20 equate to around 36 DALYs [28].
GBD 2000–2004: Improved Methods, More Data
From 1999 to 2004, WHO published an annual update of the
GBD in the World Health Report Annex tables (see for example
[29]). The update of the GBD for the year 2000 was a major input
to the assessment of healthy life expectancy for WHO Member
States, used as one of the outcome measures to quantify health
system performance in 2000 [30]. A major expansion of the work
on risk factors was released in the World Health Report 2002 [31]
and in subsequent detailed volumes in 2004 [32]. The GBD results
for the year 2001 provided a framework for cost-effectiveness and
priority setting analyses carried out for the Disease Control
Priorities Project (DCPP), a joint project of the World Bank,
WHO, and the National Institutes of Health, funded by the Bill &
Melinda Gates Foundation [33]. The GBD results were
documented in detail, with information on data sources and
methods as well as uncertainty and sensitivity analyses, in a book
published as part of the DCPP [25].
While the first GBD study was a major milestone for measuring
population health at the global level, its value for comparative
analysis was seriously limited by its use of only eight regions as the
basic units of analysis. A more refined approach was followed for
the GBD 2000 study. Country-level life tables and mortality
estimates by disease and injury cause, age, and sex were first
developed for each of the 192 WHO Member States using
different methods for countries with different availability of
mortality data. Incidence, prevalence, and YLD estimates were
developed for 17 epidemiological groupings of countries, and then
imputed to country populations using available country-level
information and methods to ensure consistency with the country-
specific mortality estimates. The resulting country-level estimates
were made available by WHO at a summarized level, and also
facilitated the production of regional estimates for any required
groupings of countries. The production of country-level estimates
also enabled substantially more engagement with countries as
a starting point for health situation assessments and national
burden of disease analyses.
New methods were developed for a number of components of
the GBD 2000, including: a new system of model life tables for
estimating age-specific death rates [34], better methods for
modeling the relationship between the level of mortality and the
broad cause structure in populations without complete death
registration data [35], better and more consistent methods for
calculating mortality and burden of disease attributable to major
risk factors, individually and in combination [36], and more
systematic approaches to the assessment of uncertainty [28]. Even
more importantly, there was a substantial increase in primary data
collected in developing countries, improved population surveil-
lance for some major diseases such as HIV/AIDS, and wider
availability of data from ‘‘verbal autopsy’’ methods, particularly in
Africa, India, and China [37].
Death registration data were available for 107 countries, the
majority of these in the high-income group, Latin America and the
Caribbean, and Europe and Central Asia. Population-based
epidemiological studies, disease registers, and notifications systems
(in excess of 2,700 datasets) also contributed to the estimation of
Figure 1. Death rates by broad cause group and region, children aged 0–4, 2002.
doi:10.1371/journal.pntd.0000114.g001
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including HIV/AIDS, malaria, tuberculosis, childhood immuniz-
able diseases, schistosomiasis, trypanosomiasis, and Chagas
disease. Almost one-third of these datasets related to sub-Saharan
Africa.
Estimating YLDs requires systematic assessments of the avail-
able evidence on incidence, prevalence, duration, and severity of
a wide range of conditions, often based on inconsistent,
fragmented, and partial data available from different studies. For
each disease and injury included in the GBD, a limited set of
disabling sequelae was selected to be evaluated in depth. Table 1
lists the disabling sequelae associated with malaria and specific
neglected tropical diseases for which YLD estimates were prepared
in the GBD 2000. Clearly, there are other sequelae for some of
these conditions that have not been directly evaluated. Addition-
ally, due to the limitations of cause assignment, particularly for
deaths, cancers and some other chronic disease long-term sequelae
are not redistributed to the initiating infectious disease in the
primary GBD cause tabulations (such re-attributions need to be
done using the counterfactual methods discussed later in this
paper). The sequelae listed in Table 1 were selected in consultation
with collaborating disease experts for direct evaluation and
represent an attempt to include all important disabling outcomes
while taking into account the limitations in the available data and
evidence.
Data sources for the GBD 2000 study included WHO disease
databases, national disease registers, epidemiological studies,
health surveys, and health facility data. Around 8,700 datasets
were used to quantify the YLD estimates for GBD 2000, of which
more than 7,000 related to communicable, maternal, perinatal,
and nutritional conditions. One-quarter of the datasets relate to
populations in sub-Saharan Africa, and around one-fifth to
populations in high-income countries. Details of data sources
and methods for specific causes are available elsewhere [37].
While the GBD 2000–2004 drew on substantially more data for
both mortality and epidemiological estimates, new systematic
reviews and estimates were not completed for all causes, and some,
such as dengue and Japanese encephalitis, continued to rely on the
original GBD assessments of the mid-1990s. Additionally, YLD
estimates for most causes continued to be based on the disability
weights estimated for the original GBD study [23]. These weights
were estimated using two forms of the person trade-off method
and asked participants in weighting exercises to make a composite
judgment about the severity distribution of the condition and the
relative value of (or preference for) each severity level on a scale
where 0 represents full health and 1 a health state equivalent to
death the preference for time spent in each severity level. This was
largely necessitated by the lack of population information on the
severity distribution of most conditions at the global and regional
levels. The participants were not representative of general
populations, but were by and large public health professionals
involved in a WHO meeting with representation from all regions
and in training workshops held in several different regions. Issues
in estimation of disability weights are further discussed in the
Discussion section below.
Disease and Injury Burden in 2002: An Overview
We present a brief overview of the results of the GBD Study for
2002 here. The findings for other years over the period 2000–2004
are very similar. Country groups used in the presentation of these
results are shown in Supplementary Table S1. Slightly over 57
million people died in 2002, 10.4 million (or nearly 20%) of whom
were children younger than five years of age. The risk of a child
dying before age five ranged from 17% in sub-Saharan Africa to
0.7% in high-income countries (Figure 1). Low- and middle-
income countries accounted for 99% of global deaths among
children under the age of five years, and 85% of these were in the
low-income countries. Only five preventable conditions—pneu-
monia, diarrheal diseases, malaria, measles, and causes arising in
the perinatal period (primarily prematurity, birth asphyxia and
trauma, and severe neonatal infections) were responsible for 70%
of all child deaths.
In developing countries, noncommunicable diseases were
responsible for more than 50% of deaths in adults aged 15–59
in all regions except South Asia and the African region, where
communicable, maternal, perinatal, and nutritional conditions
remained responsible for one-third and two-thirds of deaths,
respectively (Figure 2).
Table 2 summarizes the 20 leading causes of death and of
burden of disease globally in 2002. Ischemic heart disease and
cerebrovascular disease (stroke) were the leading causes of death in
both high-income countries and low- and middle-income countries
in 2002, together responsible for more than 20% of all deaths
worldwide. Four of the top 10 causes of death in the world were
related to smoking (ischemic heart disease, stroke, chronic
obstructive pulmonary disease, and lung cancer). In developing
countries, five of the leading 10 causes of death were infectious
diseases, including lower respiratory infections, HIV/AIDS,
diarrheal diseases, tuberculosis, and malaria.
HIV/AIDS has become the third leading cause of burden of
disease globally, and the leading cause in sub-Saharan Africa,
followed by malaria (Table 2). Communicable, maternal,
perinatal, and nutritional conditions accounted for 73% of the
burden of disease in sub-Saharan Africa, and 47% in South Asia
(Figure 3). In other low- and middle-income regions, communi-
cable, maternal, perinatal, and nutritional conditions accounted
for a little under one-quarter of the disease burden. Total disease
burden in Europe and Central Asian countries increased by nearly
40% over the period since 1990 and was higher in 2002 than for
other developing regions of the world, apart from South Asia and
sub-Saharan Africa. This increase reflects the sharp rise in adult
male mortality and disability in the 1990s, related to cardiovas-
cular disease and alcohol abuse in particular [38].
The overall burden of nonfatal disabling conditions is
dominated by a relatively small set of causes. In all regions,
neuropsychiatric conditions were the most important causes of
disability, accounting for over 37% of YLDs among adults aged
15 years and over. Vision disorders, hearing loss, and musculo-
skeletal disorders were also important causes of YLDs, in both
developed and developing countries.
Malaria, and the neglected tropical diseases specifically
estimated as separate causes in the GBD (listed in Table 3),
accounted for 1.3% of the global burden of disease (measured in
DALYs) and 2.7% of global YLDs. The neglected tropical diseases
listed in Table 3, excluding malaria, accounted for 18% of YLDs
in the African region, with lymphatic filariasis contributing most
from this group. In comparison, malaria accounted for 4.5% of
YLDs in Africa. Table 3 also summarizes GBD estimates of global
incidence and prevalence for malaria and 13 tropical diseases,
many of which might be considered ‘‘neglected.’’ Also shown are
estimates of global deaths, YLLs, YLDs, and DALYs for these
diseases.
Mathers et al. [28] have made a partial and semi-quantitative
assessment of uncertainty ranges for GBD estimates. The
uncertainty range for malaria mortality and YLLs was estimated
at around 30%, and uncertainty ranges for neglected tropical
diseases with lower case fatality rates are likely to be even larger.
Review
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GBD Cause/Sequelae Case Definition Disability Weight
Average Range
Malaria Infectious disease caused by protozoa of the genus Plasmodium 0.191 0.172–0.211
Episodes Attacks of chills, fever, and sweating due to Plasmodium infection 0.471 0.443–0.471
Anemia Defined using WHO criteria for mild to very severe anemia 0.012 0.012–0.013
Neurological sequelae Includes hemiplegia, aphasia, ataxia, and cortical blindness 0.350
Trypanosomiasis—Episodes Infection with protozoa of the genus Trypanosoma, excluding Trypanosoma cruzi 0.191 0.172–0.211
Chagas disease Infection with T. cruzi
Infection Episode of infection with T. cruzi 0.000
Cardiomyopathy without congestive
heart failure
Disorder of the heart muscle resulting from infection with T. cruzi without
congestive heart failure
0.062
Cardiomyopathy with congestive
heart failure
Disorder of the heart muscle resulting from infection with T. cruzi with
congestive heart failure
0.270 0.186–0.308
Megaviscera Dilation of interior organ in the abdominal cavity, particularly of
esophagus and colon due to T. cruzi
0.240
Schistosomiasis—Infection Infection and associated direct mortality from schistosomiasis; does not i
nclude estimates of mortality from bladder cancer, cirrhosis, or colon cancer
that may be related to schistosomiasis
0.006 0.005–0.006
Leishmaniasis Infection with flagellate protozoa of the genus Leishmania
Visceral Generalized involvement of the reticuloendothelial system 0.243
Cutaneous Presence of skin lesions (which may ulcerate) 0.023
Lymphatic filariasis Infection with filariae (Wucheria bancrofti and Brugia malayi)
Hydrocele . 15 cm Circumscribed collection of fluid in testicle or along the spermatic cord 0.073 0.066–0.075
Bancroftian lymphedema Swelling of subcutaneous tissues due to the presence of excessive lymph fluid
as a result of infection with Wucheria bancrofti
0.106 0.067–0.128
Brugian lymphedema Swelling of subcutaneous tissues due to the presence of excessive lymph fluid
as a result of infection with Brugia malayi
0.116 0.064–0.128
Onchocerciasis Infection with worms of the genus Onchocerca
Blindness Inability to distinguish the fingers of a hand at the distance of 3 meters, or
less than 5% of remaining vision as compared to a normally sighted individual
as a result of infection with Onchocerca volvulus
0.600
Itching Itchy dermatitis as a result of infection with Onchocerca volvulus 0.068
Low vision Corrected visual acuity in the better eye of less than 6/18 but better than
or equal to 3/60 due to infection with Onchocerca volvulus
0.260
Leprosy Chronic disease resulting from infection with Mycobacterium leprae
Cases Person showing clinical signs of leprosy, with or without bacteriological
confirmation of the diagnosis, and requiring chemotherapy
0.000
Disabling leprosy Grade 1 and 2 of WHO grades of disability for leprosy 0.152
Dengue Mosquito-borne disease caused by viruses of the family Flaviviridae
Dengue hemorrhagic fever Severe manifestation of dengue infection characterized by multiple hemorrhages,
and potentially followed by circulatory failure, neurological manifestations, and shock
0.210 0.195–0.211
Japanese encephalitis (JE) Mosquito-borne encephalitis caused by JE virus
Episodes Episode of JE infection 0.616 0.613–0.616
Cognitive impairment Reduced cognitive function resulting from encephalitis due to JE virus 0.468 0.402–0.484
Neurological sequelae Neurological deficits resulting from encephalitis due to JE virus 0.380 0.339–0.460
Trachoma Cases of follicular or inflammatory trachoma
Blindness Corrected visual acuity in the better eye of less than 3/60 0.600
Low vision Corrected visual acuity in the better eye of less than 6/18 but better than or
equal to 3/60
0.278 0.227–0.282
Ascariasis Infection with worms of the genus Ascaris
High-intensity infection Infection resulting in at least 20–40 worms per stool load 0.000
Contemporaneous cognitive deficit Reduction in cognitive ability in school-age children, which occurs only while
infection persists
0.006
Cognitive impairment Delayed psychomotor development and impaired performance on language
skills, motor skills, and coordination equivalent to a 5–10 point deficit in IQ.
0.463
Review
PLoS Neglected Tropical Diseases | www.plosntds.org 5 2007 | Volume 1 | Issue 2 | e114Uncertainty in YLD estimates is due to both uncertainty in
average disability weights (important particularly for high-
prevalence sequelae with low average weights) and to uncertainty
in incidence and prevalence estimates (important particularly for
focal diseases where there is considerable uncertainty about
populations at risk). Mathers et al. (Table 5.6) concluded that
uncertainty in disability weights was particularly important for
schistosomiasis, leishmaniasis, lymphatic filariasis, dengue, and the
intestinal nematode infections [28]. Although the estimates in
Table 3 have large uncertainty ranges, they do provide useful
GBD Cause/Sequelae Case Definition Disability Weight
Average Range
Intestinal obstruction Blockage of the intestines due to worm mass 0.024
Trichuriasis Infection with worms of the genus Trichuris
High-intensity infection Infection resulting in at least 250–500 worms per stool load 0.000
Contemporaneous cognitive deficit Reduction in cognitive ability in school-age children, which occurs only while
infection persists
0.006
Massive dysentery syndrome Rectal prolapse and/or tenesmus and/or bloody mucoid stools due to carpeting of
intestinal mucosa by worms
0.116 0.114–0.138
Cognitive impairment Delayed psychomotor development and impaired performance on language skills,
motor skills, and coordination equivalent to a 5-10 point deficit in IQ.
0.024
Hookworm disease Ancylostomiasis and necatoriasis
High-intensity infection Infection resulting in at least 80–160 worms per stool load 0.000
Anemia Anemia due to hookworm infection. Moderate or greater levels of anaemia are
defined as haemoglobin of,100 g/l in pregnant women, ,110 g/l in children and
adult women and ,120 g/l in adult men.
0.024
Cognitive impairment Delayed psychomotor development and impaired performance on language skills,
motor skills, and coordination equivalent to a 5-10 point deficit in IQ
0.024
Source: Mathers et al. [37], Annex Tables 3A.5 and 3A.6.
doi:10.1371/journal.pntd.0000114.t001
Table 1. cont.
Figure 2. Death rates by broad cause group and region, adults aged 15–59, 2002.
doi:10.1371/journal.pntd.0000114.g002
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Leading Causes of Death Leading Causes of Burden of Disease
Rank Cause
Deaths
(millions)
Percent of
total deaths Rank Cause
DALYs
(millions)
Percent of
total DALYs
1 Ischemic heart disease 7.21 12.6% 1 Perinatal conditions 97 6.5%
2 Cerebrovascular disease 5.51 9.7% 2 Lower respiratory infections 91 6.1%
3 Lower respiratory infections 3.88 6.8% 3 HIV/AIDS 84 5.7%
4 HIV/AIDS 2.78 4.9% 4 Unipolar depressive disorders 67 4.5%
5 Chronic obstructive pulmonary
disease
2.75 4.8% 5 Diarrheal diseases 62 4.2%
6 Perinatal conditions 2.46 4.3% 6 Ischemic heart disease 59 3.9%
7 Diarrheal diseases 1.80 3.2% 7 Cerebrovascular disease 49 3.3%
8 Tuberculosis 1.57 2.7% 8 Malaria 46 3.1%
9 Malaria 1.27 2.2% 9 Road traffic injuries 39 2.6%
10 Trachea, bronchus, lung cancers 1.24 2.2% 10 Tuberculosis 35 2.3%
11 Road traffic injuries 1.19 2.1% 11 Chronic obstructive pulmonary
disease
28 1.9%
12 Diabetes mellitus 0.99 1.7% 12 Congenital anomalies 27 1.8%
13 Hypertensive heart disease 0.91 1.6% 13 Hearing loss, adult onset 26 1.7%
14 Self-inflicted injuries 0.87 1.5% 14 Cataracts 25 1.7%
15 Stomach cancer 0.85 1.5% 15 Measles 21 1.4%
16 Cirrhosis of the liver 0.79 1.4% 16 Violence 21 1.4%
17 Nephritis and nephrosis 0.68 1.2% 17 Self-inflicted injuries 21 1.4%
18 Colon and rectum cancers 0.62 1.1% 18 Alcohol use disorders 20 1.4%
19 Liver cancer 0.62 1.1% 19 Protein-energy malnutrition 17 1.1%
20 Measles 0.61 1.1% 20 Falls 16 1.1%
Source: World Health Organization [29]
doi:10.1371/journal.pntd.0000114.t002
Figure 3. The burden of disease, by broad cause group and region, 2002.
doi:10.1371/journal.pntd.0000114.g003
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importance of mortality and disability, and on regional patterns of
disease burden.
Road traffic injuries were among the top 10 causes of DALYs
for both high-income and low- and middle-income countries.
Violence was also the fourth leading cause of burden in Latin
America and Caribbean countries. In these countries, as well as in
the Europe and Central Asian region, and the Middle East and
North Africa, more than 30% of the entire disease and injury
burden among male adults aged 15–44 was attributable to injuries,
including road traffic injuries, violence, and self-inflicted injuries.
Additionally, injury deaths were noticeably higher for women in
some parts of Asia and the Middle East and North Africa, in part
due to high levels of suicide and violence.
The GBD results clearly illustrate the ‘‘double burden’’ of
disease faced by the poorer developing countries of South Asia and
Africa. Countries that are still struggling with ‘‘old’’ and ‘‘new’’
infectious disease epidemics must now also deal with the emerging
epidemics of noncommunicable disease such as heart disease,
stroke, diabetes, and cancer.
Comparative Quantification of the Burden of
Disease from Risk Factors
Perhaps the most important methodological progress since the
GBD 1990study has been made with respect to quantification of
disease burden caused by risk factors. In the initial study, the
population health effects of 10 risk factors were quantified, but
there was limited emphasis on the comparability of the estimates.
Different risk factors have very different epidemiological traditions,
particularly with regard to defining ‘‘hazardous’’ exposure, the
strength of evidence on causality, and the availability of
epidemiological research on exposure and outcomes. Moreover,
classical risk factor research has treated exposures as dichotomous,
labeling individuals as either exposed or nonexposed, with
exposure defined according to some, often arbitrary, threshold
value. Recent evidence for such continuous exposures as
cholesterol, blood pressure, and body mass index (BMI) suggests
that such arbitrarily defined thresholds are inappropriate, since
hazard functions for these risks rise (or decline) continuously across
the entire range of measured exposure levels, with no obvious
threshold [39].
For the GBD 2000 study, a new framework for quantifying risk
factor burden was defined that measured changes in disease
burden that would be expected under different population
distributions of exposure [40]. Fractions of disease burden
attributable to a risk factor were then calculated based on
a comparison of disease burden expected under the current (i.e.,
2000) estimated distribution of exposure, by age, sex, and region,
with disease burden expected if a counterfactual distribution of
exposure had applied. To improve comparability across risk
factors, a counterfactual distribution was defined for each risk
factor as the population distribution of exposure that would lead to
the lowest levels of disease burden. Thus, for example, in the case
Table 3. Tropical Disease Mortality and Burden, Priority and Neglected Diseases, World, 2002
Disease
Incidence
(000s)
Prevalence
(000s)
Deaths
(000s)
YLLs
(000s)
YLDs
(000s)
DALYs
(000s)
YLLs per
Death
YLDs per
Case
Malaria—acute episodes 408,250 4,406 1,272 41,507 4,979 46,486 33 0.01
Lymphatic filariasis 0 10 5,768 5,777 23 3.69
Hydrocele.15 cm 1,564 38,137
Bancroftian lymphedema 798 18,953
Brugian lymphedema 150 3,434
Trachoma 0 3 2,326 2,329 18 5.32
Blindness 437 2,936
Low vision 400 3,517
Leishmaniasis 51 1,569 521 2,090 31 0.98
Visceral 534 1,508
Cutaneous 1,157 2,157 - - -
Ascariasis—high-intensity infection - 58,147 3 121 1,696 1,817 36 0.03
Schistosomiasis—infection 5,733 248,248 15 171 1,531 1,702 11 0.27
Trypanosomiasis—episodes 46 200 48 1,429 96 1,525 30 2.11
Trichuriasis—high-intensity infection - 26,624 3 106 900 1,006 35 0.03
Hookworm—high-intensity infection - 59,999 3 51 922 973 17 0.02
Japanese encephalitis—episodes 44 24 14 406 303 709 29 6.94
Chagas disease—infection 217 10,137 14 185 481 667 13 2.22
Dengue hemorrhagic fever 73 75 19 609 6 616 33 0.09
Onchocerciasis 0 0 484 484 22 8.72
Blindness 38 349
Itching 56 1,346
Low vision 47 601
Leprosy—cases 175 903 6 86 113 198 14 0.65
Source: World Health Organization [29]
doi:10.1371/journal.pntd.0000114.t003
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distribution would be 100% of the population being life-long
nonsmokers; for overweight and obesity it would be a narrow
distribution of BMI centered around an optimal level (e.g., 21
[with a standard deviation of 1] kg/m
2), and so on. The theoretical
minimum risk exposure distributions for the risk factors quantified
in the WHO Comparative Risk Assessment study (the risk factor arm of
the GBD 2000 study) were developed by expert groups for each
risk factor, together with systematic reviews and analyses of extant
sources on risk factor exposure and hazard, using an iterative
process that increased comparability across risk factors [32,41].
Results of the Comparative Risk Assessment study for the year 2000 are
summarized in Table 4.
The comparative risk assessment for 26 global risk factors,
carried out as part of the GBD 2000 study, suggests that risk
factors for communicable, maternal, perinatal, and nutritional
conditions (e.g., unsafe sex, child and maternal undernutrition,
indoor air pollution from household use of solid fuels, and poor
water, sanitation, and hygiene)—whose burden is primarily
concentrated in the low-income regions of sub-Saharan Africa
and South Asia—and risk factors for noncommunicable diseases
(e.g., smoking, alcohol, high blood pressure and cholesterol, and
overweight and obesity) are leading causes of global disease
burden, and that the latter are globally widespread (see Figures 4
and 5).
In developed countries, smoking (12.2%), high blood pressure
(10.9%), overweight and obesity (7.4%), alcohol use (9.2%), and
high cholesterol (7.6%) were the leading causes of loss of healthy
life, contributing mainly to noncommunicable diseases and
injuries. In developing countries, leading causes of burden of
disease included both risk factors affecting the poor and associated
with communicable, maternal, perinatal, and nutritional condi-
tions (e.g., childhood underweight [11.0% of disease burden in
these regions], unsafe water, sanitation, and hygiene [4.3%],
indoor smoke from household use of solid fuels [3.1%], and unsafe
sex [7.3%]), as well as risk factors for noncommunicable diseases
(e.g., high blood pressure [3.3%], smoking [2.7%], and alcohol use
[3.1%]). Undernutrition was the leading global cause of health loss
in 2000, as it was in 1990 (the 2000 results disaggregate
undernutrition into underweight and micronutrient deficiencies).
Despite substantially improved comparability in GBD 2000, the
quantification of risk factor burden needs to expand to include
a larger number of risk factors for tropical diseases, injuries, and
mental health.
Table 4. The 20 Leading Risk Factor for Deaths and Burden of Disease, World, 2000
Attributable Mortality Attributable Burden of Disease
Rank Risk Factor
Deaths
(million)
Percent of
Total Deaths Rank Risk Factor
DALYs
(Millions)
Percent of
Total DALYs
1 High blood pressure 7.1 12.8 1 Childhood and maternal
underweight
137.4 9.4
2 Smoking and oral tobacco use 4.9 8.8 2 Unsafe sex 91.9 6.3
3 High cholesterol 4.4 7.9 3 High blood pressure 64.3 4.4
4 Childhood and maternal
underweight
3.7 6.7 4 Smoking and oral tobacco
use
59.1 4.1
5 Unsafe sex 2.9 5.2 5 Alcohol use 58.3 4.0
6 Low fruit and vegetable intake 2.7 4.9 6 Unsafe water, sanitation,
and hygiene
54.2 3.7
7 Overweight and obesity (high BMI) 2.6 4.6 7 High cholesterol 40.4 2.8
8 Physical inactivity 1.9 3.4 8 Indoor smoke from
household use of solid fuels
38.5 2.6
9 Alcohol use 1.8 3.2 9 Iron deficiency 35.1 2.4
10 Unsafe water, sanitation, and
hygiene
1.7 3.1 10 Overweight and obesity
(high BMI)
33.4 2.3
11 Indoor smoke from household
use of solid fuels
1.6 2.9 11 Zinc deficiency 28.0 1.9
12 Iron deficiency 0.8 1.5 12 Low fruit and vegetable intake 26.7 1.8
13 Urban air pollution 0.8 1.4 13 Vitamin A deficiency 26.6 1.8
14 Zinc deficiency 0.8 1.4 14 Selected occupational risks
a 21.9 1.5
15 Vitamin A deficiency 0.8 1.4 15 Physical inactivity 19.1 1.3
16 Selected occupational risks
a 0.8 1.4 16 Lead exposure 12.9 0.9
17 Contaminated injections in
health care settings
0.5 0.9 17 Illicit drugs use 11.5 0.8
18 Lead exposure 0.2 0.4 18 Contaminated injections in
health care settings
10.5 0.7
19 Illicit drugs use 0.2 0.4 19 Non-use and use of ineffective
methods of contraception
8.8 0.6
20 Global climate change 0.2 0.3 20 Child sexual abuse 8.2 0.6
aIncludes occupational risk factors for injuries, occupational carcinogens and airborne particulates, ergonomic stressors and occupational noise.
Source: World Health Organization, Comparative Risk Assessment Project [32]
doi:10.1371/journal.pntd.0000114.t004
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Comprehensive Assessment
The Bill & Melinda Gates Foundation has provided funding for
a new GBD 2005 study, to be carried out over three years,
commencing in 2007. The study will be led by the new Institute
for Health Metrics and Evaluation at the University of
Washington [42], with key collaborating institutions including
Harvard University, the World Health Organization, Johns
Hopkins University, and the University of Queensland. This
study will also draw on the world’s cumulative descriptive
epidemiology expertise through a network of around 40 expert
working groups. As well as developing new and improved methods
to make full use of the increasing amount of health data,
particularly from developing countries, the GBD 2005 study will
include a comprehensive and consistent revision of disability
weights, and assess trends from 1990 to 2005, with projections to
2010. The study will be completed in 2010 and also forms part of
the Institute’s broader research portfolio on the determinants and
outcomes of health system performance assessment.
Disability weights are the crucial link by which conditions that
largely cause illness or loss of functional health can be compared
with conditions that cause mortality. These weights can have
a dramatic effect upon the final estimates, particularly for high-
prevalence mild conditions (e.g., hearing loss, visual impairment,
anemia, and cognitive impairment, sequelae for a range of
infectious and parasitic diseases). The 1990 disability weights were
typically estimated for disease sequelae averaged across the
distribution of outcomes, in some cases separately for treated
and untreated cases, and used groups of health experts rather than
general population samples. Some researchers have argued that
disability weights for specific diseases or sequelae have been
undervalued [43,44], although in many cases their arguments
relate to more severe cases rather than the average of all cases
included in the GBD case definitions. The weights have also been
criticized by groups interested in particular diseases who have
argued that some disabling sequelae have been ignored or
undervalued. While some of these concerns are valid, and need
to be addressed in the GBD 2005 revisions, it is not always easy to
obtain representative population samples of health states associ-
ated with given sequelae, particularly those with relatively low
prevalence. To prepare consistent and unbiased estimates of YLDs
by cause, it was important to ensure that the disability weight and
the population incidence/prevalence data relate to the same case
definitions.
A particular difficulty is how to measure and characterize the
average health states associated with sequelae. This is partly an
issue of the lack of information on the population-level distribution
Figure 4. Attributable mortality, by selected major risk factors and region, 2000.
doi:10.1371/journal.pntd.0000114.g004
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reasons related to the limitations of available data, the original
GBD study asked participants to make a composite judgment
about the severity distribution of the condition and the preference
for time spent in each severity level. The Dutch disability weights
project [21] has gone further in assessing disability weights for
a range of severity levels of outcomes for a particular sequela (such
as mild, moderate, and severe dementia), thus allowing the overall
final disability weight for a sequela to take account of regional
variations in the severity distribution of outcomes.
The GBD 2005 project will build on methodological advance-
ments [21,45,46] and take advantage of new data collection since
1996, which provides extensive cross-cultural data on disability
weights. The WHO Multi-Country Household Survey Study in
2001 collected health state valuation data on over 500,000 health
states from respondents in 71 countries. This has been used to
construct a health state valuation function [46]. The World Health
Survey has also included a health state valuation module, and
analysis of resulting data is under way [47]. In the next iteration of
the burden of disease analyses, it should be feasible to take health
state valuations based on such survey data, together with
descriptions of outcomes associated with disease sequelae, to
produce updated disability weights that take into account not only
the available information on health state distributions for disease
sequelae, but also the health state preferences of people from all
regions of the world.
Although this empirical work provides a much stronger basis for
measuring population disability or health state weights, several
important research issues remain. Methods for eliciting weights,
such as the time trade-off or standard gamble, often capture values
other than the level of health associated with a state: the time
trade-off method is affected by time preference, the standard
gamble method is affected by risk aversion, and choice-based
methods may elicit assessments of well-being rather than health
[48]. Another particular problem is the measurement of disability
weights for conditions of low severity but high prevalence such as
anemia and hearing loss, where the current disability weights are
small but quite uncertain and multiplied by large prevalences. A
disability weight of 0.01 will give half the burden that a disability
weight of 0.02 will yield, but no existing valuation measurement
method has precision at such low levels of loss of health.
Discussion and Conclusions
The development and widespread application of a single
summary measure of population health (DALYs) has greatly
facilitated scientific and political assessments of the comparative
importance of various diseases, injuries, and risk factors,
Figure 5. The burden of disease, by selected major risk factors and region, 2000.
doi:10.1371/journal.pntd.0000114.g005
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rankings of DALYs have led to strategic decisions by some
agencies, such as WHO, to invest greater effort in program
developments to address priority health concerns such as tobacco
control and injury prevention. The subsequent GBD 2000 study,
and a plethora of country applications, have led to substantial
improvements in both methods and data availability, as well as in
the comparability of results. Such global comparative assessments
have identified dramatic changes in global health conditions,
including impressive reductions in child and adult mortality in
many middle-income developing countries and some low-income
countries, the explosion of the HIV/AIDS epidemic during the
1990s in sub-Saharan Africa, and the dramatic worsening of adult
health and mortality risks in the former Soviet countries in the
1990s.
The comparable analyses of the GBD/Comparative Risk
Assessment 2000 frameworks have confirmed the advanced
epidemiological transition in most regions for both diseases and
their risk factors, with the possible exception of South Asia and
Africa. To the unfinished agendas of the neglected tropical
diseases, malaria, tuberculosis, HIV/AIDS, and child and
maternal mortality have been added new agendas of noncommu-
nicable disease prevention and control, injury prevention and
control, and new health threats associated with globalization and
trade, particularly tobacco.
The burden of disease methodology and the DALY measure
have stimulated considerable debate, particularly in the interna-
tional and national health policy arenas, among the health
economics and epidemiological research communities, and among
disability interest groups [13]. Criticisms of the GBD approach fall
into three main groups. First, there are concerns about the
desirability and implications of extrapolation of population health
estimates where data are limited, uncertain, or missing [14].
Second, there has been a lively debate in the literature about the
way that the DALY summarizes fatal and nonfatal health
outcomes [11,12]. Third, some well known health economists
have argued that burden of disease analysis is irrelevant or
potentially misleading for setting health priorities [11,49].
Murray and colleagues have argued that health planning,
including that based on uncertain assessments of evidence that
synthesizes the available data and information while ensuring
consistency and adjustment for known biases, will almost always be
more informed than planning based on ideology, special interests,
or crude statistics, which are often biased and inconsistent [50].
Murray has recently clarified the roles of crude, corrected, and
predicted health statistics [51]. While we strongly advocate that
corrected and predicted health statistics should be used to produce
a comprehensive and unbiased picture of the global burden of
disease for health policy and planning, we suggest that evaluation
and monitoring of health systems and interventions, on the other
hand, should be based on corrected, but not predicted, statistics.
The DALY has received a great deal of criticism from disability
advocates and some health analysts, who have interpreted the
inclusion of disability in the DALY as implying that people with
disability are less valued than people in full health [52]. The WHO
definition of health is grounded in a multidimensional notion of
health functioning, and the conceptual basis for the DALY has
moved from an original somewhat ill-defined focus on the ‘‘social
value of health’’ [23] to a focus on quantifying the loss of health
per se rather than the quality of life or well-being associated with
that loss of health [53]. Loss of health is conceptualized in terms of
domains of health functioning, which include body functions such
as fertility, respiration, vision, or pain, as well as more complex
functions such as mobility, affect, or cognition. While definitions
and concepts of disability vary widely across societies, the WHO
International Classification of Functioning, Disability and Health
[54] defines ‘‘disability’’ as an umbrella term for impairments,
activity limitations, and participation restrictions that are health-
related. According to this definition, anyone who is disabled has
a reduction in functional health and thus does not have ‘‘full
health’’ in terms of the functional health concept that the DALY
quantifies.
Some disability advocates have explicitly rejected this viewpoint
[52], apparently equating health with the absence of active disease
or pathology (in our view a narrowly medical conceptualization of
health). This probably reflects concerns that if people with
disabilities are seen as having reduced health, this may increase
discrimination in the allocation of resources. We would argue that
metrics for quantifying population health loss should incorporate
losses in health functioning: a population with high levels of
onchocerciasis-caused blindness has less health than one with low
levels, even if the current prevalence of onchocerciasis infection is
zero in both. The disability weights used in the GBD have also
been incorrectly criticized as implying that every person with
a particular health condition experiences the same health state
[52]. Of course, the average disability weights used in the GBD are
intended to represent the average health loss at population level
only, not individual level.
As used in the DALY, the term ‘‘disability’’ is essentially
a synonym for states of less than full health, conceptualized in
terms of severity-adjusted functional health loss. The term
disability was chosen to stress a vision of health that goes beyond
the absence of disease to include decreases in functioning resulting
from disease. While use of a term such as health-adjusted life years
would perhaps be more accurate, DALYs are widely used and
a name change now would lead to more confusion than clarity.
However, the DALY quantifies loss of health, and the disability
weights are thus intended to reflect social preferences for health
states, not broader valuations of ‘‘quality of life,’’ ‘‘wellbeing,’’ or
‘‘utility’’ [53]. A high disability weight for a health state then
implies that people place a high social value on preventing such
health states and says nothing whatsoever about the wellbeing,
quality of life, or value of the people experiencing such health
states.
Some health economists have expressed concern that burden of
disease analysis might result in priority setting solely on the basis of
the magnitude of disease burden, arguing that burden of disease
studies are irrelevant for priority setting and that all one needs to
know is the marginal cost-effectiveness of potential interventions
[49]. Although this view has little credibility among policy makers,
who are generally very interested in understanding the patterns
and causes of health loss in populations and their changes over
time, it is in fact a misrepresentation of the purpose of burden of
disease analysis. The original GBD study, the later round of GBD
work at WHO, and the use of GBD results in the Disease Control
Priorities Project have all been accompanied by substantial efforts
in cost-effectiveness analysis, and an explicit recognition that
health priority setting requires not only information on the size
and causes of health problems, but on the cost-effectiveness of
interventions, and on other information relating to equity and
social values [1,55,33]. Further, using a quantification of the GBD
based on DALYs and on the analysis of the health gains from
various intervention investments does not in any way imply that
the user ascribes to the view that health resources should be strictly
allocated to maximize health. In fact, the WHO framework for
health system performance assessment explicitly included sub-
stantial emphasis on reducing health, financial, and other
inequalities as an objective of health systems [56].
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evidence that there is a demand for the simplification of
epidemiological complexity that summary measures provide. Of
course, theprovision of summarymeasures does notpreclude thefull
dissemination of the underlying internally consistent incidence,
prevalence, and mortality estimates. In particular, there is consider-
abledemand for a revised GBD study that reliablymeasures changes
in global health and disease patterns over the past 15 years or so.
More money is being spent on global health than ever before—both
by governments, private foundations, and nongovernmental orga-
nizations. Advocacy groups have appreciated the value of good
comparative statistics to galvanize public support and policies, as
reflected by the increasing interest in the neglected tropical diseases.
Additionally, donors and others in the global health community are
increasingly demanding a greater understanding of trends in health
in order to better allocate their resources and make real progress in
improving health. Critical policy questions depend upon under-
standing trends. Is malaria mortality in children in Africa increasing
in the context of rising chloroquine drug resistance or not? Has there
been a resurgence of onchocerciasis in parts of Africa? Has there
been a decline in HIV mortality in populations with significant
antiretroviral treatment coverage? How much progress is being
made in the elimination of diseases such as lymphatic filariasis and
human African trypanosomiasis? Which populations are missing out
on access to effective treatments for helminthic infections? Does
research funding and priority setting neglect some areas of high
disease burden? These are important policy questions that require
new, critical analyses of the type provided by the GBD framework.
The new GBD study will also revise 1990 estimates using consistent
data and methods to assess trends in the global burden of diseases
and injuries from 1990 to 2005.
A particular challenge for the new GBD study will be the
comparative lack of information for tropical and neglected
diseases. Data availability may have worsened for some diseases.
The GBD 2000 malaria estimates and estimates for some of the
key causes of child death were forced to draw on studies of
incidence and case fatality from the 1980s and 1990s. This appears
to reflect a decline in interest by either investigators or journals in
descriptive epidemiology studies that may not be sufficiently
‘‘novel’’ for funder and journal audiences. An additional challenge
for comparative risk assessment in relation to the tropical diseases
is that ‘‘risk factors’’ for tropical diseases often have highly
heterogeneous effects across populations: for example, the risk
from not using bed-nets is highly dependent on housing and on
local ecological and meteorological factors; similarly the effects of
each environmental or socioeconomic risk factor on the prevalence
of tropical diseases such as schistosomiasis and hookworm depends
on coexistence of other risks and on geographical factors [57]. Yet
comparative measurement of the effects of risk factors for disease
and injury has significant policy potential and thus should be
further explored for this group of diseases. Therefore the analytical
and empirical work on comparative risk assessment should be
expanded to include risk factors for tropical diseases. Key research
priorities for improving our understanding of the burden of
neglected tropical diseases are listed in Box 1.
As international programs and policies to improve health
worldwide become more widespread, so too will the need for more
comprehensive, credible, and critical assessments to periodically
monitor population health and the success, or otherwise, of these
policies and programs. Repeated one-off assessments of the global
burden of disease do not provide comparability over time due to
improvements in data and methods. There is a need to move
beyond these, towards truly consistent and comparable monitoring
of the world population’s health over time. We thus welcome the
forthcoming series of reviews on the burden of neglected tropical
diseases to be published in this journal, as an important
contribution to this task.
Supporting Information
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Found at: doi:10.1371/journal.pntd.0000114.s001 (0.06 MB
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Box 1. Future Research Directions
Key issues for future research on the burden of neglected
tropical diseases include:
N Assessing the need to explicitly address additional
diseases not currently included in the GBD. The current
draftcauselistfortheGBD2005alsoincludescysticercosis,
echinococcosis, dracunculiasis, yellow fever, rabies, and
leptospirosis.
N Review of the disease sequelae quantified for each
disease to ensure that all important disabling outcomes
are captured, and also that the natural history of the
disease is appropriately modeled.
N Development of improved disease models for the
estimation of incidence and duration. For several
important diseases, the current GBD study does not
attempt to estimate incidence, and effectively assumes
that incidence equals prevalence for the calculation of
YLDs.
N Comprehensive revision of disability weights for dis-
abling sequelae incorporating population-level informa-
tion on the distribution of health states.
N Addressing the issue of so-called subtle morbidity, i.e.,
small decrements in functioning (e.g., fatigue) associated
with chronic infection.
N Development of methods for the assessment of disability
weights for highly prevalent impairments or sequelae of
low average severity (e.g., anemia, cognitive deficits).
N Development of methods to ensure that disease-specific
estimates of impairments common to a number of
disease and injury causes, such as anemia or cognitive
deficits, collectively match population-level total pre-
valences for such impairments.
N Addressing the difficult issues of assessing the incidence
and prevalence of highly focal diseases. Studies tend to
focus on areas with disease—how representative are
these studies of the whole population at-risk, what
populations are at risk, how to extrapolate to national,
regional, and global estimates of incidence and preva-
lence?
N Estimating attributable deaths due to NTDs for long-
term outcomes such as cancers, cirrhosis of the liver, and
renal failure.
N Estimating cause-specific mortality for diseases with
relatively low case fatality rates in regions without useable
death registration data. Innovative new approaches to the
use and validation of verbal autopsy instruments may be
helpful.
N Identifying key risk factors for NTD incidence and
mortality, quantifying exposure distributions for individ-
ual and multiple risk factors, and quantifying their
hazardous effects, especially when the hazardous effects
may depend on the presence of other risks.
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